Oralis SB Granted Oral Health Claim in Canada
31 May 2016 --- Canadian company Lallemand Health Solutions (LHS) has announced that their probiotic formula Oralis SB has been recognized for its benefits in dental health management by the Canadian Health Authorities, based on four randomized trials.
The following health claim has been approved by Health Canada: “Helps promote dental health through the control of Streptococcus mutans growth and plaque formation when used twice daily.”
In addition, the solution bears generic probiotic claims: Helps support intestinal/gastrointestinal health. Could promote a favorable gut flora. Source of probiotics.
The randomized trials submitted to the Canadian authorities and gathering a total of 330 children and 52 adults showed the following conclusions:
• Jindal et al. (2011): Oralis SB significantly reduces salivary S. mutans count as compared to a placebo in children. The authors concluded that Oralis SB “might be used as a suitable, easy and safe method for anti-caries prevention.”
• Jothika et al. (2015): Oralis SB used as mouthwash significantly reduces the count of cariogenic bacteria S. mutans found in the plaque in adults as compared to placebo and with similar efficacy than traditional antiseptic solutions (chlorhexidine and sodium fluoride mouthwashes).
• Thakkar et al., (2013): Oralis SB significantly reduces dental plaque formation in children, when compared to placebo, but also to chlorhexidine antiseptic mouthwash. It was concluded that Oralis SB “can be viewed as potential alternative to chlorhexidine mouthrinse for prevention of periodontal disease”.
• Purunaik et al. (2014): Oralis SB significantly reduces dental plaque formation in children as compared to placebo and chlorhexidine, and is even significantly more effective than chlorhexidine on gingivitis.
• Jindal et al. (2011): Oralis SB significantly reduces salivary S. mutans count as compared to a placebo in children. The authors concluded that Oralis SB “might be used as a suitable, easy and safe method for anti-caries prevention.”
• Jothika et al. (2015): Oralis SB used as mouthwash significantly reduces the count of cariogenic bacteria S. mutans found in the plaque in adults as compared to placebo and with similar efficacy than traditional antiseptic solutions (chlorhexidine and sodium fluoride mouthwashes).
• Thakkar et al., (2013): Oralis SB significantly reduces dental plaque formation in children, when compared to placebo, but also to chlorhexidine antiseptic mouthwash. It was concluded that Oralis SB “can be viewed as potential alternative to chlorhexidine mouthrinse for prevention of periodontal disease”.
• Purunaik et al. (2014): Oralis SB significantly reduces dental plaque formation in children as compared to placebo and chlorhexidine, and is even significantly more effective than chlorhexidine on gingivitis.
Altogether, these results indicate that this specific combination of Lactobacillus rhamnosus Rosell-11, Lactobacillus helveticus Rosell-52, Bifidobacterium longum Rosell-175 and Saccharomyces boulardii yeast represent a natural and effective approach to dental health prevention.
LHS has bases in more than 60 countries across 5 continents. Oralis SB is part of LHS’s portfolio of probiotics for Oral Health. Lallemand Inc. specializes in the development, production and marketing of yeast and bacteria, as well as other ingredients linked to these microorganisms or their markets.
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
